Review: Evaluating combination therapies for asthma: pros, cons, and comparative benefits
Combination therapies with inhaled corticosteroids (ICS) and either long-acting β2 agonists (LABA) or leukotriene receptor antagonists (LTRA) are commonly used to help patients maintain control of their asthma. LABA and LTRA have different mechanisms of action and both provide complementary benefits...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2008-06-01
|
| Series: | Therapeutic Advances in Respiratory Disease |
| Online Access: | https://doi.org/10.1177/1753465808092280 |
| _version_ | 1828765310520393728 |
|---|---|
| author | Leif Bjermer |
| author_facet | Leif Bjermer |
| author_sort | Leif Bjermer |
| collection | DOAJ |
| description | Combination therapies with inhaled corticosteroids (ICS) and either long-acting β2 agonists (LABA) or leukotriene receptor antagonists (LTRA) are commonly used to help patients maintain control of their asthma. LABA and LTRA have different mechanisms of action and both provide complementary benefits when combined with ICS. This paper compares the two regimens based on recent clinical trial data, evaluates their efficacy on various clinical and quality of life outcomes, and discusses the importance of therapy choice in people with specific asthma phenotypes. The potential of new dosing strategies, including adjustable maintenance therapy and single-inhaler maintenance and reliever therapy is also reviewed. Given the variety of outcomes, phenotypes, and treatment strategies that must be considered, the importance of individualized management is emphasized. |
| first_indexed | 2024-12-11T06:45:46Z |
| format | Article |
| id | doaj.art-dd730f714d14416c99ff56efe49f4f89 |
| institution | Directory Open Access Journal |
| issn | 1753-4658 |
| language | English |
| last_indexed | 2024-12-11T06:45:46Z |
| publishDate | 2008-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Respiratory Disease |
| spelling | doaj.art-dd730f714d14416c99ff56efe49f4f892022-12-22T01:17:05ZengSAGE PublishingTherapeutic Advances in Respiratory Disease1753-46582008-06-01210.1177/1753465808092280Review: Evaluating combination therapies for asthma: pros, cons, and comparative benefitsLeif BjermerCombination therapies with inhaled corticosteroids (ICS) and either long-acting β2 agonists (LABA) or leukotriene receptor antagonists (LTRA) are commonly used to help patients maintain control of their asthma. LABA and LTRA have different mechanisms of action and both provide complementary benefits when combined with ICS. This paper compares the two regimens based on recent clinical trial data, evaluates their efficacy on various clinical and quality of life outcomes, and discusses the importance of therapy choice in people with specific asthma phenotypes. The potential of new dosing strategies, including adjustable maintenance therapy and single-inhaler maintenance and reliever therapy is also reviewed. Given the variety of outcomes, phenotypes, and treatment strategies that must be considered, the importance of individualized management is emphasized.https://doi.org/10.1177/1753465808092280 |
| spellingShingle | Leif Bjermer Review: Evaluating combination therapies for asthma: pros, cons, and comparative benefits Therapeutic Advances in Respiratory Disease |
| title | Review: Evaluating combination therapies for asthma: pros, cons, and comparative benefits |
| title_full | Review: Evaluating combination therapies for asthma: pros, cons, and comparative benefits |
| title_fullStr | Review: Evaluating combination therapies for asthma: pros, cons, and comparative benefits |
| title_full_unstemmed | Review: Evaluating combination therapies for asthma: pros, cons, and comparative benefits |
| title_short | Review: Evaluating combination therapies for asthma: pros, cons, and comparative benefits |
| title_sort | review evaluating combination therapies for asthma pros cons and comparative benefits |
| url | https://doi.org/10.1177/1753465808092280 |
| work_keys_str_mv | AT leifbjermer reviewevaluatingcombinationtherapiesforasthmaprosconsandcomparativebenefits |